These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

923 related articles for article (PubMed ID: 16477396)

  • 41. Toward more effective drug regulation.
    Schmidt AM
    FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532
    [No Abstract]   [Full Text] [Related]  

  • 42. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
    Giordani A; Kobel W; Gally HU
    Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GMPs and GCPs: a topical comparison.
    Allen LV
    Int J Pharm Compd; 2013; 17(1):87. PubMed ID: 23627250
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmaceutical GMPs.
    Bobrowicz G
    Qual Assur; 1994 Jun; 3(2):138-48. PubMed ID: 7804629
    [No Abstract]   [Full Text] [Related]  

  • 45. WHO expert committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1984; 704():1-54. PubMed ID: 6437087
    [No Abstract]   [Full Text] [Related]  

  • 46. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementing United States Pharmacopeia Chapter <1163>. Quality assurance in pharmaceutical compounding, Part 3: Testing.
    Allen LV
    Int J Pharm Compd; 2012; 16(4):322-8. PubMed ID: 23050393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combating counterfeit drugs.
    Lancet; 2008 May; 371(9624):1551. PubMed ID: 18468523
    [No Abstract]   [Full Text] [Related]  

  • 49. Use of microbiology in drug monitoring.
    Kirshbaum A
    Bull Parenter Drug Assoc; 1971; 25(5):226-32. PubMed ID: 5109889
    [No Abstract]   [Full Text] [Related]  

  • 50. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
    Raman NV; Prasad AV; Ratnakar Reddy K
    J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Technicoscientific evolution and current direction of the standards regulating drug registration in Italy and in the European Economic Community].
    Battaglino G
    Boll Chim Farm; 1978 Jun; 117(6):313-24. PubMed ID: 743380
    [No Abstract]   [Full Text] [Related]  

  • 54. World agencies try to stem flood of fake drugs.
    Surendran A
    Nat Med; 2004 Feb; 10(2):111. PubMed ID: 14760401
    [No Abstract]   [Full Text] [Related]  

  • 55. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report.
    World Health Organization
    World Health Organ Tech Rep Ser; 2007; (943):1-156. PubMed ID: 17621973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 2003; 917():i-viii, 1-125, back cover. PubMed ID: 15024913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Guidelines and strategy of the International Conference of Harmonization (ICH) and its member states to overcome existing impurity control problems for antibiotics in China.
    Jiang Y; Xia JP; Yang JH; Zhang ZF; Hu CQ; Zhang ZR
    Chin J Nat Med; 2015 Jul; 13(7):498-506. PubMed ID: 26233840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quality assurance for medical products: unified program for all federal agencies.
    Flaherty FJ
    Hosp Formul; 1976 Dec; 11(12):669, 674, 679. PubMed ID: 1028796
    [No Abstract]   [Full Text] [Related]  

  • 59. Compounding pharmacies: before and after an inspection.
    Kulkarni D; Ricketts S
    Int J Pharm Compd; 2013; 17(5):358-62. PubMed ID: 24459779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.